- About Us
- My Account
The views expressed are those of the author at the time of writing. Other teams may hold different views and make different investment decisions. The value of your investment may become worth more or less than at the time of original investment. While any third-party data used is considered reliable, its accuracy is not guaranteed. For professional, institutional, or accredited investors only.
Asset managers can help drive progress by conducting deep research to support the projects with the best prospects of fueling impactful results.
The world faces a host of daunting challenges, from the lingering pandemic to the effects of climate change. And yet, I can’t help but remain optimistic about the potential for science and innovation to solve some of our most pressing issues. After all, over three decades of investing in health care, I’ve seen firsthand the power that new ideas, backed by research and capital, have to cure diseases, produce lifesaving vaccines, and improve patient outcomes.
The same spirit of progress is solving problems on a global scale. In my view, we are in the early days of an age of innovation driving real-world solutions, tangible progress, and long-term growth.
Let’s start with the industry I know best. My colleagues and I are as excited as ever about the countless disruptive technologies poised to reshape health care. Today, scientists are tackling disease-causing biology at unprecedented rates and with novel modalities. Decades of research have led us to what I believe is one of the most promising moments in the history of health care, where ideas that once seemed like science fiction are quickly becoming a reality.
In cancer, antibody drug conjugates now allow oncologists to attach a chemotherapy to an antibody and deliver treatment in a more targeted, efficacious, and tolerable way. Likewise, targeted protein degradation can hijack the body’s “garbage disposals” to eliminate proteins that cause specific diseases. This enables treatments that go after targets that were not previously addressable by traditional means.
In my view, as we approach this new frontier in health care, it is easy to be hopeful. The near future will see the potential for technologies like RNA interference and gene therapy to cure numerous rare and serious diseases. In the wake of the pandemic, mRNA vaccines and related technology could combat viruses far beyond COVID, such as RSV and the flu. Finally, artificial intelligence and machine learning are poised to help researchers rapidly identify new treatment targets and drugs at a speed that outpaces traditional drug discovery methods.
At the same time, I believe one of the world’s biggest challenges — climate change — will increasingly be tackled by innovative technological solutions. At Wellington Management, climate risk is an integral part of our research. Through our partnerships with the Woodwell Climate Research Center and MIT, we are constantly integrating physical and transition risks into our analysis. Combining the scientific insights of these organizations with our in-depth industry research, we’re putting capital behind climate technology innovations that could help the world mitigate and adapt to the problems posed by a changing climate.
The next generation of community solar and integrated circuit panels offers new hardware solutions to the energy crisis. Groundbreaking alternative meat substitutes will make the food we eat more sustainable while AI-powered recycling will help to limit waste around the globe. These are just a few of the technological developments that will be brought to bear in the battle against climate change and the pursuit of a more sustainable future.
Health care and climate change are just two of innumerable areas where the private sector is powering much-needed progress. I believe asset managers and asset owners have a key role to play in this progress by providing capital to disruptive companies across public and private markets.
There are countless innovators attempting to solve the world’s problems and limited capital to fund these projects. Asset managers can positively influence these efforts by conducting deep research to support the projects with the best prospects of fueling impactful results.
It is crucial to confront the world’s greatest challenges with a realistic understanding of the tasks in front of us. But I also believe we must remain optimistic about the potential for big ideas to tackle these issues head on. Though the problems we face are understandably top of mind, it’s important to remember the innovative thinkers working tirelessly in the background. In my view, as we enter the age of innovation, human ingenuity is more than capable of overcoming the challenges ahead.
Featured Unique Perspectives
Driving positive outcomes: Our 2022 ESG research agenda
Director of ESG Research Carolina San Martin highlights key areas of focus for 2022, including talent management, supply chain accountability, and climate action — particularly with respect to biodiversity.
Sustainable Investment Outlook
Our head of Sustainable Investment shares key areas of focus for 2023, including climate change and biodiversity, modern slavery, data privacy, shareholder rights, and impact investing,
Full speed ahead: China’s race to implement AI
"China's AI landscape is dynamic and evolving rapidly. While challenges and uncertainties persist, China's commitment to AI innovation positions itself as a formidable player in the global AI arena." Yash Patodia, Global Industry Analyst and Terry Chen, Equity Research Analyst
Macro implications of the AI revolution: is the market right?
Macro Strategist John Butler sets out an initial framework to help answer key questions about the potential macro impact of artificial intelligence.
Investing at the biopharma frontier
Rebecca Sykes details groundbreaking innovations happening today in the biopharmaceutical industry. She explains key advancements and the investment landscape for therapies targeting diabetes, cancer, and Alzheimer's disease, three of the deadliest and most expensive diseases facing the world today.
Private investing portfolio company interview with AMP Robotics CEO
Dr. Matanya Horowitz, CEO of AMP Robotics, highlights how the company integrates AI and robotics into the recycling industry and explores the “actionable guidance” Wellington provides on ESG and other strategic issues.
Thematic investing focus: a new era for medical innovation
Advances in science, tools and technologies are transforming the face of healthcare, revolutionising the diagnosis and treatment of complex diseases. How can thematic investors identify promising opportunities?
Generative AI: Separating hype from opportunity
Two of Wellington's tech experts join host Thomas Mucha to discuss the rapidly evolving AI landscape and separate hype from reality, highlighting everything from the industries most likely to be impacted to AI's geopolitical implications.
What AI could mean for fixed income
Fixed Income Portfolio Manager Brij Khurana details the potential effects of artificial intelligence on the fixed income market.
Seven observations on the latest US/China executive order
Geopolitical Strategist Thomas Mucha shares his analysis of the recent Biden administration executive order, which aims to restrict investment into certain sectors in China, and details the potential investment implications.
The great American labor shortage: Causes, consequences, and solutions
Shifting demographics suggest that US labor markets will remain tight in years to come, with major implications for income inequality, investment spending, and government policy.
Biotech for the next decade: Private market innovations
We explore our latest research in private biotech innovation across immunomodulatory therapies, precision oncology, antibody drug conjugates, radiopharmaceuticals, genetic medicines, and a range of other novel treatment modalities.